Jasper G van den Boorn Selected Research

monobenzone (Benoquin)

1/2016	Inflammasome-Dependent Induction of Adaptive NK Cell Memory.
8/2011	Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity.
6/2011	Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy.
5/2010	Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jasper G van den Boorn Research Topics

Disease

6	Melanoma (Melanoma, Malignant) 01/2016 - 05/2006
5	Neoplasms (Cancer) 01/2016 - 05/2006
3	Vitiligo 08/2011 - 08/2006
1	Contact Dermatitis (Eczema, Contact) 01/2016
1	Pathologic Processes 03/2013
1	Weight Loss (Weight Reduction) 05/2006

Drug/Important Bio-Agent (IBA)

4	monobenzone (Benoquin)FDA Link 01/2016 - 05/2010
3	AntigensIBA 06/2011 - 08/2006
2	Cancer VaccinesIBA 07/2013 - 05/2006
2	VaccinesIBA 07/2013 - 05/2006
1	LigandsIBA 01/2016
1	Natural Killer Cell ReceptorsIBA 01/2016
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 01/2016
1	Blocking AntibodiesIBA 07/2013
1	MicroRNAs (MicroRNA)IBA 03/2013
1	TetraspaninsIBA 03/2013
1	HaptensIBA 06/2011
1	quinone (benzoquinone)IBA 06/2011
1	Proteins (Proteins, Gene)FDA Link 06/2011
1	Differentiation AntigensIBA 06/2011
1	Monophenol Monooxygenase (Tyrosinase)IBA 06/2011
1	Skin Lightening PreparationsIBA 05/2010
1	Imiquimod (Aldara)FDA LinkGeneric 05/2010
1	Therapeutic UsesIBA 05/2010
1	Vaccine AdjuvantsIBA 05/2006
1	Interleukin-23 (Interleukin 23)IBA 05/2006
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2006
1	CytokinesIBA 05/2006
1	Protein Subunit VaccinesIBA 05/2006

Therapy/Procedure

4	Immunotherapy 07/2013 - 05/2010
2	Therapeutics 05/2010 - 05/2006
1	Withholding Treatment 05/2010